Plinabulin – Triple Combos

Plinabulin
Triple Combos

Plinabulin + PD-1 + CTLA-4

In the second quarter of 2018, in collaboration with Rutgers University, we commenced an investigator-initiated Phase 1/2 trial of Plinabulin in combination with PD-1 and CTLA-4 antibodies as a treatment for SCLC. This study will investigate whether the addition of Plinabulin results in a reduction of immune-related side effects of PD-1 and CTLA-4 antibodies and provides efficacy synergy.

Plinabulin + Chemo + PD-1

In the second quarter of 2018, in collaboration with Johns Hopkins University, we commenced an investigator-initiated Phase 1/2 trial of Plinabulin in combination with pembrolizumab and platinum-based chemotherapy agents as a first-line treatment for NSCLC. This study will investigate whether the addition of Plinabulin results in a reduction of immune-related side effects of PD-1 antibodies and a reduction in severe neutropenia caused by platinum-based chemotherapy.

Clinical Trials

For details of these two trials, please visit the below website.

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer